Citation

Widnes SF, Schjøtt J. Am. J. Obstet. Gynecol. 2016; 216(4): 375-378.

Affiliation

Regional Medicines and Pharmacovigilance Centre (RELIS Vest), Haukeland University Hospital, Bergen, Norway; Section of Pharmacology, Department of Clinical Science, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway; Section of Clinical Pharmacology, Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway.

Copyright

(Copyright © 2016, Elsevier Publishing)

DOI

10.1016/j.ajog.2016.12.007

PMID

27988271

Abstract

Pregnant women, but also physicians, have unrealistically high perceptions of teratogenic drug effects. This may result in suboptimal treatment of disease, and even influence decisions of whether or not to continue pregnancy. In order to attain more realistic teratogenic risk perceptions, several factors that influence this issue should be considered, and these are further discussed in this Clinical Opinion. Importantly, drug use may have several benefits, both for the pregnant woman's health and to avoid negative fetal effects of untreated maternal disease. A greater focus on this aspect may act to balance risk perceptions. Furthermore, both pregnant women and physicians need access to drug information sources that provide realistic risk estimates, in order to increase confidence in appropriate drug use and prescribing. We suggest that access to decision support and individually-tailored information provided by drug information centers may contribute to this goal.

Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Language: en